SPOTLIGHT: Merck sub-licenses Cubicin in Japan

A Japanese subsidiary of Merck has licensed Cubist's antibiotic Cubicin. Cubist gains $6 million up front for the Japanese rights and will get up to $39.5 million more in milestones for a successful development program. Release

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.